Forging New Partnerships: Aquilant Appointed as UK Distributor for CamPROBE®

Aquilant is delighted to announce a new partnership with Medovate and J.E.B. Technologies, becoming the UK distributor for CamPROBE® – a groundbreaking medical device set to transform prostate cancer diagnostics.

CamPROBE® (Cambridge Prostate Biopsy Device) is an innovative technology developed for performing transperineal prostate biopsies under local anaesthetic and help provide a more comfortable experience for patients.

Developed by Professor Vincent Gnanapragasam and his team at the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, CamPROBE® has already received regulatory approval and in clinical use. Its straightforward, cost-effective design and ergonomic features mark a significant advancement in prostate biopsy procedures.

“CamPROBE® has the potential to offer a safer, well tolerated method for conducting prostate biopsies,” said Stuart Thomson, Vice President of Business Development at Medovate and J.E.B. Technologies. 

 “This distribution agreement opens the door for wider adoption across the UK, giving more men access to the alternative prostate biopsy approaches they deserve.” 

Key benefits of the CamPROBE® device include:

• Transperineal access that reduces infection risk vs transrectal methods.
• Simultaneous local anaesthetic delivery through an integrated needle.
• Can be angled and repositioned to reach potentially difficult areas of the prostate.
• Less invasive approach, with just two puncture points and low patient pain scores.
• Specifically designed to make access easy and intended to reduce the risk of needle stick injuries.

“We are delighted to affiliate with Medovate and JEB to bring this important innovation to healthcare professionals across the United Kingdom. With prostate cancer remaining a significant health concern, improving access to safer, more effective devices and equipment that can be used in the prostate biopsy and cancer diagnostic pathway is vital. This collaboration reflects our shared commitment to advancing men’s health innovation” said Steve Matthews, UK Sales Director, HC21 UK.

This partnership marks an important step in bringing the benefits of CamPROBE® to more patients across the UK and may pave the way for wider NHS adoption of safer, more modern prostate cancer diagnostic tools.